CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
Yahoo Finance · Nov 3, 2026 · Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
Not investment advice. Headline and summary only, not a full reprint.